Display options
Cite
Piciu D, Pestean C, Barbus E, et al. Second malignancies in patients with differentiated thyroid carcinoma treated with low and medium activities of radioactive I-131. Clujul Med. 2016;89(3):384-9doi: 10.15386/cjmed-636.
Piciu, D., Pestean, C., Barbus, E., Larg, M. I., & Piciu, A. (2016). Second malignancies in patients with differentiated thyroid carcinoma treated with low and medium activities of radioactive I-131. Clujul medical (1957), 89(3), 384-9. https://doi.org/10.15386/cjmed-636
Piciu, Doina, et al. "Second malignancies in patients with differentiated thyroid carcinoma treated with low and medium activities of radioactive I-131." Clujul medical (1957) vol. 89,3 (2016): 384-9. doi: https://doi.org/10.15386/cjmed-636
Piciu D, Pestean C, Barbus E, Larg MI, Piciu A. Second malignancies in patients with differentiated thyroid carcinoma treated with low and medium activities of radioactive I-131. Clujul Med. 2016;89(3):384-9. doi: 10.15386/cjmed-636. Epub 2016 Jul 28. PMID: 27547058; PMCID: PMC4990434.
Copy Download .nbib Format: NLM
Share it on

Clujul Med. 2016;89(3):384-9. doi: 10.15386/cjmed-636. Epub 2016 Jul 28.

Second malignancies in patients with differentiated thyroid carcinoma treated with low and medium activities of radioactive I-131.

Clujul medical (1957)

Doina Piciu, Claudiu Pestean, Elena Barbus, Maria Iulia Larg, Andra Piciu

Affiliations

  1. Department of Nuclear Medicine and Endocrinology, Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania; Department of Nuclear Medicine and Endocrinology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  2. Department of Medical Oncology, Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania; Department of Medical Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

PMID: 27547058 PMCID: PMC4990434 DOI: 10.15386/cjmed-636

Abstract

BACKGROUND AND AIM: This study aimed at determining whether there is a risk regarding the development of second primary malignancies after patient exposure to the low and medium radioiodine activity used during the treatment of differentiated thyroid cancers (DTC).

METHODS: Second primary malignancies that occurred after DTC were detected in 1,990 patients treated between 1970 and 2003. The mean long-term follow-up period was 182 months.

RESULTS: Radioiodine I-131was administrated at a mean dose of 63.2 mCi. There were 93 patients with at least one second primary malignancy. The relative risk of development of second malignancy in DTC patients was increased (p<0.0001) for breast, uterine and ovarian cancers compared with the general population.

CONCLUSIONS: The overall risk concerning the development of second primary malignancies was related to the presence of DTC, but not to exposure to the low and medium activities of radioiodine administered as adjuvant therapy.

Keywords: iodine radioisotopes; neoplasms; second primary; thyroid cancer

References

  1. Endocrine. 2013 Oct;44(2):426-33 - PubMed
  2. Clin Nucl Med. 2011 Apr;36(4):277-82 - PubMed
  3. Eur J Cancer. 2013 Apr;49(6):1374-403 - PubMed
  4. J Clin Endocrinol Metab. 2006 May;91(5):1819-25 - PubMed
  5. Clin Lab Haematol. 1993;15(1):55-8 - PubMed
  6. C R Acad Sci III. 1999 Feb-Mar;322(2-3):205-13 - PubMed
  7. Minerva Endocrinol. 2013 Sep;38(3):269-79 - PubMed
  8. Clin Nucl Med. 2012 Feb;37(2):214-5 - PubMed
  9. Br J Cancer. 2003 Nov 3;89(9):1638-44 - PubMed
  10. J Natl Compr Canc Netw. 2013 May;11(5 Suppl):705-7 - PubMed
  11. Eur J Endocrinol. 2006 Jun;154(6):787-803 - PubMed
  12. Acta Oncol. 2013 Aug;52(6):1055-61 - PubMed
  13. Haematologica. 2012 Aug;97(8):e28-9; author reply e30 - PubMed
  14. Lancet. 2013 Mar 23;381(9871):1046-57 - PubMed
  15. Endocr J. 2012;59(6):489-96 - PubMed
  16. J Clin Endocrinol Metab. 2013 Apr;98(4):1353-60 - PubMed
  17. Thyroid. 2010 Jun;20(6):647-51 - PubMed
  18. J Clin Endocrinol Metab. 2008 Feb;93(2):504-15 - PubMed
  19. Laryngorhinootologie. 2001 May;80(5):253-6 - PubMed
  20. Nat Clin Pract Endocrinol Metab. 2008 Apr;4(4):180-1 - PubMed
  21. Surgery. 2012 Jun;151(6):844-50 - PubMed
  22. Haematologica. 1998 Aug;83(8):767-8 - PubMed
  23. Med Pediatr Oncol. 1995 Feb;24(2):82-6 - PubMed
  24. J Clin Endocrinol Metab. 2010 Apr;95(4):1516-27 - PubMed

Publication Types